| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/23/2006 | CA2577026A1 Orally administered small peptides synergize statin activity |
| 02/23/2006 | CA2577022A1 Compositions and methods using hyaluronic acid and hyluronidase inhibitors |
| 02/23/2006 | CA2576993A1 Bisaryl-sulfonamides |
| 02/23/2006 | CA2576619A1 Benzothienopyridines for use as inhibitors of eg5 kinesin |
| 02/23/2006 | CA2576599A1 Substituted hydantoins |
| 02/23/2006 | CA2576589A1 Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid |
| 02/23/2006 | CA2576584A1 2 - {-3-`2-(phenyl)-oxazol-4-ylmethoxymethyl!-cyclohexylmethoxy}-propionic acid derivatives used as ppar ligandes (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes |
| 02/23/2006 | CA2576561A1 Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments |
| 02/23/2006 | CA2576554A1 N-(phenyl-oxazol-4-ylmethoxymethyl)-cyclohexyl-succinic acid amide derivatives and related compounds which are used as ppar-ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes |
| 02/23/2006 | CA2576545A1 2 - { - 3 2 - (phenyl)-oxazol-4-ylmethoxyl-cyclohexylmethoxy}-propionic acid derivatives used as ppar ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes |
| 02/23/2006 | CA2576531A1 1,5-diphenylpyrazoles |
| 02/23/2006 | CA2576530A1 Noncardiotoxic pharmaceutical compounds |
| 02/23/2006 | CA2576421A1 Inhibitors of hcv replication |
| 02/23/2006 | CA2576388A1 Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity |
| 02/23/2006 | CA2576274A1 Para-alkyl-substituted n-(4-hydroxy-3-methoxybenzyl)-cinnamic acid amides and the use thereof for the preparation of medicinal drugs |
| 02/23/2006 | CA2576269A1 Combinations for the treatment of diseases involving cell proliferation |
| 02/23/2006 | CA2576233A1 Conjugate comprising an antagomir and a ligand |
| 02/23/2006 | CA2576222A1 Compositions and methods for treating lymphoma |
| 02/23/2006 | CA2576156A1 Use of xenon as neuroprotectant in a neonatal subject |
| 02/23/2006 | CA2576091A1 Indole derivatives comprising an acetylene group as ppar activators |
| 02/23/2006 | CA2576049A1 Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning |
| 02/23/2006 | CA2576042A1 Immune stimulatory infant nutrition |
| 02/23/2006 | CA2575979A1 Novel serotonin receptor ligands and their uses thereof |
| 02/23/2006 | CA2575848A1 Medicament for the treatment of central nervous system disorders |
| 02/23/2006 | CA2575842A1 A composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases |
| 02/23/2006 | CA2575826A1 Compounds and compositions useful as cathepsin s inhibitors |
| 02/23/2006 | CA2575821A1 Dihydropteridinone infusion solution having a long shelf life |
| 02/23/2006 | CA2575787A1 Dihydropteridinones for the treatment of cancer diseases |
| 02/23/2006 | CA2575785A1 5-ht7 receptor antagonists |
| 02/23/2006 | CA2575771A1 5-ht7 receptor antagonists |
| 02/23/2006 | CA2575737A1 Tanaproget derivatives, metabolites, and uses thereof |
| 02/23/2006 | CA2575706A1 Vitamin b12 compositions |
| 02/23/2006 | CA2575563A1 Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
| 02/23/2006 | CA2575561A1 Amido compounds and their use as pharmaceuticals |
| 02/23/2006 | CA2575560A1 Chemical compounds |
| 02/23/2006 | CA2575466A1 Thiazole based inhibitors of atp-utilizing enzymes |
| 02/23/2006 | CA2575385A1 Aerosol formulation for inhalation, containing an anticholinergenic agent |
| 02/23/2006 | CA2575367A1 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
| 02/23/2006 | CA2575188A1 Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer |
| 02/23/2006 | CA2575155A1 Use of vitamin ds to treat kidney disease |
| 02/23/2006 | CA2575153A1 Use of vitamin d receptor activators or vitamin d analogs to treat cardiovascular disease |
| 02/23/2006 | CA2575056A1 Selected fused heterocyclics and uses thereof |
| 02/23/2006 | CA2575033A1 Novel biaromatic compounds that activate ppar type receptors, and use thereof in cosmetic or pharmaceutical compositions |
| 02/23/2006 | CA2575029A1 Novel biaromatic compounds which activate receptors of ppar type and their use in cosmetic or pharmaceutical compositions |
| 02/23/2006 | CA2574279A1 Heterocyclic compounds as pharmaceutical agents |
| 02/23/2006 | CA2574156A1 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/23/2006 | CA2574081A1 Methods and materials for treating mental illness |
| 02/23/2006 | CA2574078A1 Ophthalmic compositions for treating ocular hypertension |
| 02/23/2006 | CA2574045A1 Medical device for delivering biologically active material |
| 02/23/2006 | CA2574040A1 Iap binding compounds |
| 02/23/2006 | CA2574035A1 Histone deacetylase inhibitors |
| 02/23/2006 | CA2573974A1 Tgf-.beta. gene expression inhibitor |
| 02/23/2006 | CA2573819A1 Heterocyclic dye compounds for in vivo imaging and diagnosis of alzheimer's disease |
| 02/23/2006 | CA2573772A1 Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
| 02/23/2006 | CA2573764A1 Hydantoin derivatives for the treatment of inflammatory disorders |
| 02/23/2006 | CA2573761A1 Use of estrogen related receptor-modulating aryl ethers |
| 02/23/2006 | CA2573758A1 Bis-quaternary ammonium salt corrosion inhibitors |
| 02/23/2006 | CA2573730A1 1,2,3,4-tetrahydropyrazin-2-yl acetamides and their use as bradykinin antagonists for the treatment of inflammation related disorders |
| 02/23/2006 | CA2573714A1 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/23/2006 | CA2573699A1 Compounds and their preparation for the treatment of alzheimer's disease by inhibiting beta-amyloid peptide production |
| 02/23/2006 | CA2573688A1 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane |
| 02/23/2006 | CA2573562A1 Compositions and methods related to heart failure |
| 02/23/2006 | CA2573457A1 4-(2-methoxy-phenoxy)-2-trifluoromethyl-benzonitrile as an androgen modulator |
| 02/23/2006 | CA2573454A1 Use of flibanserin for the treatment of anorexia nervosa |
| 02/23/2006 | CA2573370A1 Inhalable medicaments containing corticosteroids, betamimetic and an anticholinergenic |
| 02/23/2006 | CA2573271A1 Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| 02/23/2006 | CA2573185A1 Methods for treating hepatitis c |
| 02/23/2006 | CA2567782A1 Heterocyclic condensed compounds useful as antidiuretic agents |
| 02/23/2006 | CA2564616A1 Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
| 02/23/2006 | CA2541747A1 Ascophyllum compositions and methods |
| 02/22/2006 | EP1627883A1 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A derivatives |
| 02/22/2006 | EP1627880A1 Boronic ester and acid compounds, synthesis and uses |
| 02/22/2006 | EP1627879A1 Process for preparing hydrohalogen metal complexes of specific particle size |
| 02/22/2006 | EP1627876A1 Heterocyclic condensed compounds useful as antidiuretic agents |
| 02/22/2006 | EP1627875A1 Method for producing cyclic diamine derivative or salt thereof |
| 02/22/2006 | EP1627873A1 Benzofuran compound and medicinal composition containing the same |
| 02/22/2006 | EP1627869A1 Amide derivative |
| 02/22/2006 | EP1627663A2 Use of a pharmaceutical composition for the treatment of pathologies derived from infection by herpes virus, papillomavirus, hepatitis virus, viral neuralgia, viral dsyplasia, immune-deficiency-induced viral infections and viral neuritis. |
| 02/22/2006 | EP1627646A1 Cleaning and disinfecting agent for medical instruments with improved effectiveness against Hepatitis B Virus |
| 02/22/2006 | EP1627644A1 PREPARTAION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND INTERLEUKIN-1a PRODUC TION INHIBITOR |
| 02/22/2006 | EP1627640A1 Sulfate group transferase inhibitor |
| 02/22/2006 | EP1627639A2 Use of COX-2 inhibitors for the treatment of affective disorders |
| 02/22/2006 | EP1627638A1 Fortifier |
| 02/22/2006 | EP1627637A1 Ophthalmic solution containing quinolone antimicrobial compound |
| 02/22/2006 | EP1627636A1 Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| 02/22/2006 | EP1627635A2 Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection |
| 02/22/2006 | EP1627634A1 Composition for lowering lipid in body |
| 02/22/2006 | EP1627633A1 Oral pharmaceutical forms of administration with a delayed action with tramadol |
| 02/22/2006 | EP1627632A1 Therapeutic agent |
| 02/22/2006 | EP1627631A2 Morphine sulphate microgranules, method for preparing same and composition comprising same |
| 02/22/2006 | EP1627217A2 Cdkl1 as modifier of branching morphogenesis and methods of use |
| 02/22/2006 | EP1627048A2 Compositions for down-regulation of ccr5 expression and methods of use therefor |
| 02/22/2006 | EP1627047A2 Methods for facilitating recovery of functions of endogenous or implanted or transplanted stem cells using high molecular weight hyaluronic acid |
| 02/22/2006 | EP1626989A2 Method of treating corneal transplant rejection by using vegf antagonists |
| 02/22/2006 | EP1626980A1 Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids |
| 02/22/2006 | EP1626973A1 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo 3.2.0]heptane is an effective analgesic agent |
| 02/22/2006 | EP1626970A1 Azabicycloalkane compounds as muscarinic receptor antagonists |
| 02/22/2006 | EP1626967A1 Substituted pyrazoles |
| 02/22/2006 | EP1626966A1 Benzofuran inhibitors of factor viia |
| 02/22/2006 | EP1626964A2 New benzimidazole derivatives |